• Innoviva, Inc. recently launched Nortiva Bio, a wholly owned clinical-stage subsidiary built around the LYNX long-acting oral drug delivery platform acquired from Lyndra Therapeutics in 2025, and Innoviva Specialty Therapeutics signed an exclusive agreement with Dr. Reddy's Laboratories to distribute and license XACDURO in selected international markets.
• Together, these moves broaden Innoviva's exposure to advanced drug delivery technologies while extending the commercial footprint of its hospital-focused anti-infective portfolio through a global partner.
• Next, we’ll consider how the creation of Nortiva Bio shapes Innoviva’s investment narrative and longer-term profile in differentiated therapeutics.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Innoviva's Investment Narrative?

For Innoviva, the investment case still rests on a cash‑generative royalty base, disciplined capital returns and selective bets on differentiated therapeutics. The launch of Nortiva Bio and the XACDURO partnership with Dr. Reddy’s add more moving parts to that story. In the near term, the key catalysts remain execution on existing respiratory royalties, progress in the hospital anti‑infective franchise and how actively management uses the buyback program versus its at‑the‑market equity facility. The Dr. Reddy’s deal could incrementally support those commercial catalysts if international uptake of XACDURO builds, while Nortiva introduces fresh clinical and execution risk alongside any longer‑term upside from the LYNX platform. With earnings forecasts pointing to profit pressure over the next few years, investors now need to weigh that richer R&D profile against Innoviva’s currently low earnings multiple.

However, one specific execution risk around Nortiva’s clinical programs is easy to underappreciate and deserves attention. Innoviva's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$35 to almost US$58 per share, underlining how differently private investors see Innoviva. Set that against the current focus on integrating Nortiva Bio and scaling XACDURO internationally, and you can see why it helps to weigh several viewpoints before deciding how this story might affect future performance.

Explore 2 other fair value estimates on Innoviva - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Innoviva research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Innoviva research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Innoviva's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.